Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
종목 코드 GKOS
회사 이름Glaukos Corp
상장일Jun 25, 2015
CEOMr. Thomas William Burns
직원 수995
유형Ordinary Share
회계 연도 종료Jun 25
주소1 Glaukos Way
도시ALISO VIEJO
증권 거래소NYSE Consolidated
국가United States of America
우편 번호92656
전화19493679600
웹사이트https://www.glaukos.com
종목 코드 GKOS
상장일Jun 25, 2015
CEOMr. Thomas William Burns
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음